China biotech deals - SinoDrugWatch

Argo Biopharma

Novartis Deepens RNAi Partnership with Argo Biopharma in $5.36B Cardiovascular Deal

Argo Biopharma and Novartis struck their third RNAi deal, focused on cardiovascular assets. With $160M upfront and $5.36B milestone potential, the collaboration spans ANGPTL3, dyslipidemia siRNAs, and IND-ready hepatic candidates.

Outbound Deals

China’s Biotech Boom: Top Outbound Deals Signal Global Innovation Leadership

Witness the new era of global biotech collaboration as China's top outbound deals inject billions into innovation. From 3SBio's $1.25B Pfizer licensing to BioNTech's acquisition of Biotheus, explore key themes in bispecifics, ADCs, and strategic partnerships.

Bispecific Antibodies

Bispecific Antibodies in Oncology and Beyond: Clinical Advances, Market Growth, and China’s Emergence

Bispecific antibodies are reshaping oncology and beyond. By 2025, 20 products are approved, with 2024 sales topping $126.5B led by Hemlibra and Vabysmo. China leads the pipeline with 35+ trials, two domestic approvals, and global partnerships.